Global Congenital Adrenal Hyperplasia Market Report to 2032 – Insights, Epidemiology and Forecasts –

Global Congenital Adrenal Hyperplasia Market Report to 2032 – Insights, Epidemiology and Forecasts –

Global Congenital Adrenal Hyperplasia Market Report to 2032 – Insights, Epidemiology and Forecasts –

DUBLIN–(BUSINESS WIRE)–The “Congenital Adrenal Hyperplasia – Market Insight, Epidemiology And Market Forecast – 2032” report has been added to’s offering.

The congenital adrenal hyperplasia (CAH) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted congenital adrenal hyperplasia (CAH) market size from 2019 to 2032, segmented by seven major markets.

The report also covers the current congenital adrenal hyperplasia (CAH) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Companies Mentioned

  • Neurocrine Biosciences
  • Diurnal Limited
  • Spruce Biosciences
  • Adrenas Therapeutics
  • Millendo Therapeutics

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: corticosteroids, mineralocorticoids, and androgens.

  • Corticosteroids: steroid hormones that gauge the body’s response to illness or injury
  • Mineralocorticoids: steroid hormones that regulate salt and water levels
  • Androgens: male sex hormones

An enzyme deficiency will make the body unable to produce one or more of these hormones, resulting in the overproduction of another type of hormone precursor to compensate for the loss.

The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene responsible for 21-hydroxylase result in different enzyme levels, producing a spectrum of effects. CAH due to 21-hydroxylase deficiency is responsible for 95% of all cases of CAH and is broken down further into two subcategories: classical CAH, which can be sub-divided into the salt-losing form or the simple-virilizing form, and non-classical CAH. Classical CAH is by far the more severe form and can result in adrenal crisis and death if not detected and treated.

Non-classical CAH is milder and may or may not present symptoms. Since the absence of 21-hydroxylase makes the individuals unable to make the hormone cortisol and, in the case of salt-losing CAH, aldosterone, the body produces more androgens which cause a variety of symptoms, such as abnormal genital development in infant girls. There are other much rarer forms of CAH as well, including 11-Beta hydroxylase deficiency, 17a-hydroxylase deficiency, 3-Beta-hydroxysteroid dehydrogenase deficiency, congenital lipoid adrenal hyperplasia, and p450 oxidoreductase deficiency which all present different symptoms. Although CAH is not curable, as long as patients receive adequate care and treatment, they can go on to lead normal lives.

The goal of medical treatment of CAH differs by the patient’s age. CAH is a recessive gene, so both the mother and father must be recessive carriers. Couples with recessive CAH genes may prevent CAH through preimplantation genetic diagnosis.

Congenital Adrenal Hyperplasia (CAH) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the congenital adrenal hyperplasia (CAH) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The congenital adrenal hyperplasia (CAH) Market Report gives a thorough understanding of congenital adrenal hyperplasia (CAH) by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for congenital adrenal hyperplasia (CAH) in the US, Europe, and Japan.

Scope of the Report

  • The report covers the descriptive overview of congenital adrenal hyperplasia (CAH), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight is provided into the congenital adrenal hyperplasia (CAH) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for congenital adrenal hyperplasia (CAH) is provided, along with the assessment of new therapies, which will impact the current treatment landscape
  • A detailed review of the congenital adrenal hyperplasia (CAH) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global congenital adrenal hyperplasia (CAH) market

Report Highlights

  • In the coming years, the congenital adrenal hyperplasia (CAH) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence congenital adrenal hyperplasia (CAH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for congenital adrenal hyperplasia (CAH). The launch of emerging therapies will significantly impact the congenital adrenal hyperplasia (CAH) market.
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for congenital adrenal hyperplasia (CAH).
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900